Compare ADMA Biologics Inc (ADMA) vs American Homes 4 Rent Class A (AMH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs American Homes 4 Rent Class A — how do they compare? ADMA Biologics Inc trades at $9.22 (market cap $2.13B), while American Homes 4 Rent Class A trades at $33.39 (market cap $12.23B). The key difference: American Homes 4 Rent Class A is far larger — about 5.7× ADMA Biologics Inc's market cap, and American Homes 4 Rent Class A pays a 3.88% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | AMH | |
|---|---|---|
Market Cap | $2.13B | $12.23B |
Sector | Health | Real Estate |
52-Week High | $20.38 | $36.74 |
52-Week Low | $7.60 | $27.38 |
Enterprise Value | $2.20B | $17.32B |
Dividend Yield | — | 3.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
AMH trades at $34.00, down 0.23% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $35.41. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.35 exceeding expectations of $0.1763. Revenue grew to $1.85 billion in 2025, with a net income margin of 25.27%, while the stock trades at a P/E of 27.45 and P/S of 6.69. A dividend of $0.33 per share is scheduled for payment on June 30, 2026.
AMH presents a positive outlook driven by consistent earnings performance and robust fundamentals, though elevated valuation ratios and high debt levels pose risks. Investor sentiment is supported by bullish analyst ratings and strong occupancy rates in the single-family rental market, but macroeconomic factors and interest rate sensitivity remain key considerations for potential investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About American Homes 4 Rent Class A
American Homes 4 Rent is a real estate investment trust primarily focused on acquiring, operating, and leasing single-family homes as rental properties throughout the United States. The company's real estate portfolio is largely comprised of single-family properties in urban markets in the Southern and Midwestern regions of the U.S. American Homes 4 Rent's land holdings also represent a sizable percentage of its total assets in terms of value. The company derives the vast majority of its income in the form of rental revenue from single-family properties through short-term or annual leases. The firm's largest geographical markets include Dallas, Texas
Read more on AMH →
